Skip to Content
Merck

Domperidone, a new dopamine antagonist.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (1986-09-01)
M C Champion, M Hartnett, M Yen
ABSTRACT

Domperidone is a dopamine antagonist that has recently been released in Canada. Unlike metoclopramide hydrochloride, the other available dopamine antagonist, it does not readily enter the central nervous system. Domperidone acts as both an antiemetic and an upper gastrointestinal tract prokinetic agent. It is rapidly absorbed after oral administration, and few side effects have been reported. Domperidone has been approved for use in Canada for the symptomatic management of upper gastrointestinal tract motility disorders and to prevent gastrointestinal symptoms associated with the use of dopamine agonist agents in Parkinson's disease. The pharmacologic features, indications and side effects of domperidone are reviewed.

MATERIALS
Product Number
Brand
Product Description

Domperidone, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Domperidone, powder, ≥98% (HPLC)